PartnershipJun 25, 2026, 07:31 AM
Plus Therapeutics' CNSide Signs Elevance Health Deal, Covers 45.4M
AI Summary
Plus Therapeutics, Inc. announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC, has signed a national agreement with Elevance Health, Inc. This deal, effective May 1, 2026, extends coverage for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximately 45.4 million people across the United States. This expansion brings the total contracted coverage for the CNSide® CSF TCE assay to 126 million people, significantly broadening access to its diagnostic platform for leptomeningeal metastases.
Key Highlights
- CNSide Diagnostics signed a national agreement with Elevance Health, Inc.
- Agreement covers approximately 45.4 million people in the U.S.
- Total contracted coverage for CNSide® CSF TCE assay now 126 million people.
- Agreement became effective on May 1, 2026.
- Over 11,000 CNSide® tests performed at 120+ U.S. cancer institutions since 2020.
- CNSide® assay demonstrated 92% sensitivity and 95% specificity.
- The test influences treatment decisions in 90% of cases.
Price Impact
More from PSTV